Barfar Eshagh, Rashidian Arash, Hosseini Hamed, Nosratnejad Shirin, Barooti Esmat, Zendehdel Kazem
1)Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 2)Health Promotion Research Center, School of Public Health, Zahedan University of Medical Sciences, Zahedan,
1)Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 3)Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Arch Iran Med. 2014 Apr;17(4):241-5.
Breast cancer is the most common cancer among women. Mammography screening has been used in many countries to reduce early deaths caused by breast cancer. It is important to ensure that screening programs are effective and efficient. We conducted a study to assess the cost-effectiveness of a national breast cancer screening program implemented in Iran.
The perspective of the present study was the health system. Over 26,000 women aged 35 and higher, of low socioeconomic background were recruited from ten cities in the program. We used case-finding as the outcome indicator for assessing effectiveness of the program. We measured the service provision costs, the coordination costs and supervision costs of the program that included the staff costs, and measured cost per detected case. We also conducted sensitivity analyses and calculated false-positive rates as a result of the screening program.
The total cost of breast cancer screening program was estimated at $377,797. The program resulted in the identification of 24 patients with breast cancers, not different from baseline expectations without a screening program. The cost per cancer detected was calculated $15,742. The minimum and maximum cost per breast cancer detected were about $13,524 and $16,947, respectively. We observed a false-positive rate of 7.5% among the target population.
Our findings suggest that the mammography screening program was not cost-effective. Although there were technical efficiency issues in the conduct of the program, the findings do not support the implementation of national mammography screening programs in Iran in women aged less than 50 years. Careful studies of such programs for higher age groups are also recommended before they are rolled-out nationally.
乳腺癌是女性中最常见的癌症。许多国家已采用乳房X光检查筛查来减少由乳腺癌导致的早期死亡。确保筛查项目有效且高效很重要。我们开展了一项研究以评估在伊朗实施的全国性乳腺癌筛查项目的成本效益。
本研究采用卫生系统视角。从该项目的十个城市招募了26000多名35岁及以上、社会经济背景较低的女性。我们将病例发现作为评估该项目有效性的结果指标。我们测量了该项目的服务提供成本、协调成本和监督成本(包括员工成本),并计算了每例检测出病例的成本。我们还进行了敏感性分析,并计算了筛查项目导致的假阳性率。
乳腺癌筛查项目的总成本估计为377797美元。该项目发现了24例乳腺癌患者,与没有筛查项目时的基线预期无差异。每例检测出癌症的成本计算为15742美元。每例检测出乳腺癌的最低和最高成本分别约为13524美元和16947美元。我们在目标人群中观察到7.5%的假阳性率。
我们的研究结果表明乳房X光检查筛查项目不具有成本效益。尽管该项目实施过程中存在技术效率问题,但研究结果不支持在伊朗对50岁以下女性实施全国性乳房X光检查筛查项目。在全国推广之前,也建议对年龄较大人群的此类项目进行仔细研究。